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ABSTRACT
 T cell leukemia virus type 1 (HTLV-1 ) is the etiological agent responsible of a severe form 
of  hematologic malignancy designated Adult T cell Leukemia/Lymphoma or ATLL and of a 
neurological syndrome designated HTLV Associated Myelopathy/Tropical Spastic 
Paraparesis or HAM/TSP. Although the major documented viral oncogenic product of 
HTLV-1 is the Tax-1 protein, it has been recently demonstrated that also HBZ (HTLV-1 bZIP 
factor), a protein encoded by the minus strand of HTLV-1 genome, is involved in the 
pathogenesis of ATL. The full role played by HBZ in oncogenesis is still to be explored in 
detail mainly owing to the unavailability of tools to study this protein in naturally infected 
cells and in ATLL cells and its interaction with other crucial cellular proteins involved in the 
homeostasis of cell activation and proliferation. By the use of the first reported monoclonal 
antibody against HBZ generated in our laboratory we have carefully analyzed HBZ protein 
expression, sub-cellular localization as well as its interaction in vivo with endogenous cell 
factors in various HBZ-expressing cells, including in particular HTLV-1-infected cells and 
ATLL tumor cell lines. We also demonstrated the ability of this monoclonal antibody to detect 
HBZ in fresh PBMCs of HTLV-1 infected patients. The availability of this newly generated 
anti-HBZ mAb has allowed for the first time the quantization of HBZ at the single cell level in 
naturally infected cells and in neoplastic cells, a better definition of HBZ expression, 
localization and functional involvement in the biology of HTLV-1 infected cells. The findings 
described in this thesis may help to better understand the mechanisms through which viral 
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1. INTRODUCTION                                        
1.1 HTLV-1 virus 
The human T-cell lymphotropic virus type 1 (HTLV-1) is the first described human 
retrovirus and belongs to  the deltaviridae family, subfamily oncovirus type C. Retroviruses 
are RNA viruses that use an enzyme called reverse transcriptase to produce DNA from their 
RNA. The newly produced DNA is subsequently incorporated into the host’s genome. After 
integration retroviral particles can be produced and spread from cell to cell. The virion is 
about 100 nm in diameter and spherical in shape (Verdonck K et al.; 2007). The icosahedral 
capsid contains the viral RNA, and is within the protein inner envelope. The outermost layer 
is the lipid layer which is of host origin and contains the viral trans-membrane and surface 
proteins (Figure 1).  
                                 HTLV-1 is an oncogenic retrovirus that infects more than 20 million 
people worldwide (1,3). So far seven different HTLV-1 genotype (HTLV-1 a to HTLV-1 g) 
have been recognized (Verdonck K et al.; 2007). Beside HTLV-1 the Deltaretrovirus family 
include HTLV-2, HTLV-3, and HTLV-4; the simian T-cell lymphotropic viruses (STLV-1, 
STLV-2, and STLV-3) and the bovine leukemia virus (Matsuoka M et al., 2007). HTLV-1 is 
thought to be an old virus which originated in Africa, following multiple cross-species 
transmission from simians to humans some 27,000 years ago (Van Dooren S et al., 2001). It 
continued to spread overland to Asia, by sea routes to the Far East and by slave trade to 
America. The infection is now endemic in sub-Saharan Africa, Caribbean, South America, 
Japan, Melanesia and Middle East (Verdonck K et al., 2007). A curious observation is that 
within the endemic areas, the virus clusters in certain ethnic groups (Cooper , 2009). 
The virus is transmitted by sexual contact, blood transfusion and vertically from mother to 
child. Worldwide, the major mode is sexual and the most efficient mode of transmission is 
blood transfusion (Bhigjee AI et al., 2014).  
        
 
Figure 1: HTLV-1 virus as seen by electron microscope (left). Retrovirus structure (right) 
1.2 Associated diseases 
HTLV-1 was the first retrovirus associated with human diseases (Poiesz BJ et al., 1980). 
HTLV-1 causes a fatal Adult T-cell leukemia/lymphoma (ATLL) that targets preferentially 
CD4+ T cells. The identification of HTLV-1 as the etiological agent of ATLL has allowed a 
detailed analysis of the epidemiological, immunological and clinical characteristics of  this 
pathologic status (Takatsuki K et al., 1994). There are 4 clinical subtypes of ATL: 
smoldering, chronic, acute and lymphoma-type ATL (Satoshi T et al., 2004). Approximately 
5% develop of HTLV-1 infected people develop ATL (Arisawa K et al., 2000) and another 
2%-3% develop chronic inflammatory diseases involving the central nervous system (HTLV-
associated Myelopathy/Tropical Spastic Paraparesis or HAM/TSP), the eyes (Mochizuki M et 
al., 1992), the lungs (Sugimoto M et al., 1987), the joints (Nishioka K et al., 1989), or the 
skeletal muscles (Higuchi I et al., 1993); most infected individuals, however, remain healthy 
in their lifetime (healthy asymptomatic carriers: HCs).  
                                         Although the factors that cause these different manifestations of 
HTLV-1 infection are not fully understood, previous population studies suggested that both 
viral and host genetic factors influence the outcome of infection (Bangham CR et al., 2005). 
Moreover, although HTLV-1 primarily infects CD4+ T cells, other cell types in the 
peripheral blood of infected individuals have been found to contain HTLV-1, including 
CD8+ T cells, dendritic cells and B cells. HTLV-1 entry is mediated through interaction of 
the surface unit of the virion envelope glycoprotein (SU) with its cellular receptor GLUT1, a 
glucose transporter, on target cells (Manel N et al., 2003). HTLV-1.  
                                        
Fig 2: Adult-T cell leukemia flower cells (left) and ulceration (right).  
           Source: American Society of Hematology 
1.3 HTLV-1 genome organization 
The genome organization of all retroviruses is similar and includes gag, pro, pol, env genes 
(5' to 3'). The structural protein of the virion is encoded by gag, the viral protease is encoded 
by pro, reverse transcriptase enzyme is encoded by pol and the virion envelope glycoprotein 
is encoded by env (Figure 3). Interestingly, HTLV-1 genome encodes for additional proteins 
that play a crucial role not only in the HTLV-1 genome expression but also in deregulation of  
host cell genome. The HTLV-1 genome expression is regulated by two regulatory genes, rex 
and tax, located in the 3' region of viral genome. Tax plays a key role in transactivation of 
viral transcription (Franklin A et al., 1995) (Thébault S et al., 2001). Rex plays a role in the 
transport of viral RNAs at the post-transcriptional level (Hidaka M et al., 1988). The other 
accessory genes encoded by the pX region are located between env and 3' LTR and  include 
p30, p12, p21 and p13 (Franchini G et al., 2003). All these proteins are encoded by the plus-
strand viral RNA.  
                            Tax is certainly the best studied viral protein and is clearly implicated in the 
mechanisms leading to neoplastic transformation of the infected cells. Indeed Tax activates 
the nuclear factor k-B (NF-kB) pathway, cAMP response element-binding protein (CREB), 
activator protein-1 (AP-1) and serum responsive factor (SRF) (Yoshida M et al., )  from 
one side while inactivates p53 and by this inhibits apoptosis (Suzuki T et al., 1999). All these 
activities contribute to the uncontrolled proliferation of the cell (Franchini G et al., 2003).  
 
Fig 3: Genome organization of HTLV-1 provirus and functions of encoded proteins (Chan 
JK et al., 2012, Immunol Rev.)
1.4 The HTLV-1 bZIP factor, HBZ protein 
The HTLV1 RNA genome also encodes a protein from the complementary strand (Gaudray 
G et al., 2002) designated HTLV-1 bZIP factor (HBZ). HBZ contains a bZIP domain in 
addition to an activation (N-terminus) and a central domain (Hivin P et al., 2005) (Figure 4). 
There are two different isoforms of this protein: a spliced form containing 206 amino acids 
(sp) and an unspliced form with 209 amino acids (us). The sp form is more abundant than the 
us form, is found in almost all ATL patients and its promoter is activated by the transcription 
factor SP1 (Yoshida M et al., 2008). Spliced HBZ is functionally stronger than unspliced 
HBZ in inhibiting transcription from viral 5 LTR. Promoters of spHBZ and usHBZ are 
TATA-less and the transcription of spHBZ gene is relatively constant without Tax (Yoshida 
M et al., 2008). Indeed, HBZ was first identified as a protein interacting with CREB-2 via its 
bZIP domain and strongly inhibiting the CREB-2/Tax-1 interaction instrumental for the 
activation of HTLV-1 LTR (Gaudray G et al., 2002). Studies on the kinetics of HTLV-1 gene 
expression revealed nuclear retention of HBZ mRNAs (Rende F et al., 2011). Inhibition of T 
cell proliferation has been attributed to HBZ mRNA (Satou Y et al., 2006). 
                                                     
                                        
Fig 4: Different domains of HBZ protein (top). Functions associated with different HBZ 
domains (bottom: modified from Zhao T et al., 2012, Frontiers in microbiology)                                          
                                                                    
In addition to interacting with CREB-2, experiments using cells transfected with tagged HBZ 
have shown that HBZ binds to different proteins of the JUN family via its bZIP domain, 
experiments using cells transfected with tagged-HBZ have shown that HBZ binds to different 
proteins of the JUN family via its bZIP domain (Usui T et al., 2008). The binding to JunB 
and cJun induces a sequestration of these factors in nuclear bodies or an accelerated 
degradation of them. As a result HBZ reduces the cJun/JunB-mediated  transcriptional 
activation of a series of genes. Conversely, the binding of HBZ to JunD does not inhibit the 
JunD-mediated transcriptional activation of target genes; indeed HBZ-JunD complex 
upregulates even the expression of HBZ encoding gene (Basbous J et al., 2003; Mastumoto J 
wt al., 2005; Hivin P et al., 2007).   Interestingly, in many cases HBZ exerts opposite effects 
with respect to Tax-1 on signaling pathways (Figures 5 and 6). HBZ interacts with the KIX 
domain of p300/CBP to disregulate their interaction with cellular factors and/or inhibit tax-
dependent viral transactivation (Clerc I et al., 2008; Cook P R et al., 2011). HBZ inhibits, 
while Tax-1 activates, the classical NFkB pathway by inducing PDLIM2 expression which 
brings about proteasomal degradation of RelA (Zhao T et al., 2009). HBZ suppresses, while 
Tax-1 activates,  Wnt pathway by interacting with the disheveled-associating protein with a 
high frequency of Leucine residues (DAPLE) (Ma G et al., 2012). HBZ inhibits production of 
Th1 cytokines (IFN-γ particularly) by interacting with NFAT and thus impairing cell-
mediated immunity (Sugata K et al., 2012). Mice transgenic for HBZ showed an induced 




 Treg cells, 
implicating its role in T cell lymphoma and inflammation in vivo (Satou Y et al.; 2011). 
                                   Conversely, HBZ enhances the effect of certain molecules and/or 
pathways. It  activates telomerase by interacting with JunD and up-regulating the expression 
of hTERT (Kuhlmann A S et al., 2007); it enhances the TGF beta signaling pathway by 
interacting and forming a ternary complex with Smad3 and p300 (Zhao T et al., 2011). 
 
                          
Fig 5: Mainstream HBZ activity (Matsuoka M et al., 2007)                     
                          
Fig 6: Pleiotropic effects of HBZ. Green and red represents pathways/ molecules activated 
and suppressed by HBZ respectively.   
 
1.5 Mechanism of infection 
HTLV-1 establishes a robust infection in CD4+ T lymphocytes (Kannian P et al., 2012). 
There is an increase in proviral load and Tax, Gag and Env (Fig. 7) during the initial stages of 
infection. This increase in viral proteins induces a humoral response and CTL activity in the 
host which eliminates most of the HTLV-1 infected cells (Macnamara A et al., 2010). HBZ 
might play a crucial role at this stage by down-regulating Tax-dependent viral transcription 
and rescuing the infected cells from host immune response (Barbeau B et al., 2013). Thus 
HBZ favors the establishment of persistent infection by conferring a survival advantage to 
HBZ-expressing cells (Arnold J et al., 2006). Although HBZ is not required for the 
immortalization of the infected cells, HBZ is important for proliferation of infected cells. 
Another observation clearly shows that HBZ transcript itself might be necessary for induced 
IL-2-independent T cell proliferation. (Satou Y et al., 2006). 
            
 
Fig 7: Proposed mechanism of HTLV-1 infection (Barbeau B et al., 2013).   
 
2. AIMS OF THE STUDY 
Most of the reported sub-cellular localizations, biochemical interactions with cellular 
components and consequent functional implications related to HBZ described above have 
been deduced by investigating cells transfected with HBZ in which the protein is usually 
overexpressed. The lack of suitable reagents such as monoclonal antibodies against the 
native, endogenous HBZ has not permitted to corroborate and validate all the functions 
attributed to HBZ, particularly in naturally HTLV-1 infected cells and in tumor cells of 
ATLL patients. The aim of this study was to fill-up this gap by generating a monoclonal 
antibody which can identify HBZ both in HBZ-transfected cells and, most importantly, in 
HTLV-1 infected and in ATLL tumor cells. This has allowed a more precise assessment of 
the subcellular localization of HBZ as well as  its quantification in vivo both in HTLV-1 
infected and in ATLL tumor cells and launched the premises for  a better delineation of the 






3. MATERIALS AND METHODS 
3.1 HBZ constructs 
The recombinant HBZ plasmid  pGEX2T-HBZ, used to prepare the recombinant GST-HBZ 
protein used for immunization (see below), was a gift of Dr. Lemasson, Univ East Carolina, 
USA (Clerc I et al., 2008). The myc-tagged  and Hist-tagged HBZ were a gift of Dr. 
Matsuoka, Univ. of Kyoto, Japan (Satou Y et al., 2006). Full length and mutant fragments of 
GFP-tagged HBZ were provided by Dr. Mesnard, Montpellier, France (Hivin P et al., 2007).   
To purify the recombinant protein (GST-HBZ), we used Pierce agarose glutathione beads 
(Thermo scientific, Rockford, USA). The beads were mixed with the supernatant of the 
bacterial lysate and incubated overnight on a rotor wheel at 4 C. Next day the beads were 
washed and the recombinant protein was eluted with elution buffer (Tris 50mM, Nacl 
150mM pH 8, reduced glutathione 10mM).  
 
3.2 Cells  
COS and 293T cell lines were cultured in DMEM medium, supplemented with 10% fetal calf 
serum (FCS) and glutamine. HTLV-1 chronically infected cell line C5MJ (Balestrieri E, 
2008) was kindly obtained from Dr. Macchi, University of Rome Tor Vergata and maintained 
in RPMI-FCS 10% . The ATL tumor cell line ATL-2s was obtained from Dr. Matsuoka, 
Japan (Takeda S et al., 2004).  Peripheral blood monuclear cells (PBMC)  PH961 were from 
an ATL patient, under the epidemiological control of the Pasteur Institute, Paris, France. The 
immunophenotype of  C5MJ, ATL-2s and patient PH961 PBMC was assessed by 
immunofluorescence and flow cytometry (BD FACSAria II™ apparatus) as described 
(Pellegrini FP et al., 2012) using monoclonal antibodies specific for HLA class I, HLA class 
II DR, CD3, CD4, CD8, CD25, CD19, CD16, CD127.  
 
3.3 Mice immunization and generation of mAbs against HBZ 
Immunization procedure and generation of monoclonal antibodies were essentially as 
described (Accolla RS et al., 1980). Six-week-old female BALB/c mice were injected 
intraperitoneally on day1 and day20 with 250 µl of a solution containing 10 µg of HBZ-GST 
protein with equal volume of Freund’s Complete Adjuvant . On days 43 and 68, injections 
were repeated with Freund’s Incomplete Adjuvant. Mouse serum was checked for anti-HBZ 
positivity before sacrificing on day 72. Total splenocytes were fused with 10 million P3U1 
myeloma cells in presence of PEG as described (Accolla RS et al., 1980). The hybridomas 
were grown in RPMI complete medium with HAT (Hypoxanthine Aminopterin Thymidine) 
selection. Initial screening of hybridoma supernatants was performed by an indirect enzyme 
linked immunosorbent assay (protein detector ELISA kit, KPL). Briefly, 100µl of purified 
GST-HBZ protein (diluted in coating solution at 1µg/ml) was adsorbed onto the plate for 1h 
at RT. The plate was then blocked with 1x blocking solution for 1h at RT. The supernatant of 
the hybridoma to be tested was then added and incubated for 1h at RT. Peroxidase-labeled 
goat anti-mouse IgG was used as a secondary antibody. Finally the substrate and stop 
solution were added successively and the plate was read at 405 nm with a spectrophotometer. 
The mouse serum from immunized animals was used as a positive control and the supernatant 
of myeloma cells P3U1 or normal mouse serum served as a negative control. Hybridoma 
supernatants were screened for anti-HBZ positivity by western blot as well. To this purpose 
cell lysates from Cos cells transfected with myc-tagged HBZ (see below) was run on a 10% 
SDS-PAGE gel and transferred onto nitrocellulose membrane (Amersham high bond ECL, 
GE, buckinghamshire, UK). The membrane was then quenched in 5% non fat milk in 1X 
TBS containing 0.05% Tween-20 (MTTBS) for 1h at room temperature. Hybridoma 
supernatant was diluted 1:1 with 5% MTTBS and used as primary antibody at 4 C O.N. After 
appropriate washes with MTTBS, HRP conjugated goat anti-mouse IgG was used as 
secondary antibody for 1h at room temperature. The membranes were developed by ECL 
system (Pierce, Rockford, USA) and exposed to X-ray film. A similar protocol was used for 
analyzing HBZ mutants and C5MJ/ ATL-2s lysate 
To determine the antibody isotype, we used Pierce rapid ELISA mouse mAb isotyping kit. 
Appropriately diluted hybridoma supernatant was added to the wells pre-coated with anti-
mouse heavy or anti-mouse light chain capture antibody. Goat anti-mouse IgG+IgM+IgA 
HRP conjugate was then added to the wells and incubated for 1 hr at room temperature. 
Following washes; TMB substrate and stop solution were added following manufacturer’ 
instructions and finally the color developed was read at 450 nm.    
 
3.4 Transfection procedures 
COS cells or 293T cells were transfected with full length HBZ constructs (GFP-HBZ or myc-
HBZ) or GFP-tagged  HBZ fragments (∆ZIP, ∆AD, BR1, DBD, BR1-BR2-DBD)  as 
previously described (Tosi G et al, 2011). COS and 293T cells were seeded in 35-mm-
diameter plates and transfected with 1-3 µg of plasmid DNA constructs using Lipofectamine 
(Invitrogen). Cell extracts were prepared 24 h posttransfection and analyzed for the 
expression of recombinant proteins by SDS-PAGE and Western blotting with the following 
antibodies: anti-Myc (9E10; Santa Cruz Biotechnology) to detect myc-tagged HBZ  and anti-
turboGFP (Origene) to detect GFP-tagged full length or fragment HBZs. Horseradish 
peroxidase (HRP)-conjugated anti-mouse immunoglobulin or anti-rabbit immunoglobulin 
secondary antibodies (Amersham) were used. Blots were developed by chemiluminescence 
assay (Immune-Star HRP substrate; Bio-Rad). 
  
3.5 Quantitative assessment of HBZ in chronically infected and in ATLL 
tumor cell lines  
Endogenous HBZ expression was quantitated by using the anti-HBZ monoclonal antibody 
4D4-F3.  To this purpose a standard curve with increasing concentrations of purified GST-
HBZ protein was constructed and visualized by western blot with the anti-HBZ mAb. Cell 
lysates from both endogenously HBZ-producing cells and HBZ transfected cells were then 
assayed for the presence of HBZ by western blot and relative intensities compared by 
densitometry with those obtained in the standard curve. The deduced concentration of HBZ in 
cells was obtained by taking into account the total number of cells used for preparing the cell 
lysate, the volume of cell lysate used and the percentage of positive cells visualized by 
confocal microscopy. The obtained number in amount/cell was then converted in number of 
moles/cell taking into account the molecular weight of endogenous HBZ (assumed as 26.000 
dalton), and transfected myc-tagged HBZ (myc-HBZ, 36.000 dalton) by the formula:  [ 
HBZgr / HBZmw = HBZmoles ]. Mole value (HBZmoles) was then transformed in number of 
molecules/cell by multiplying it for the Avogadro number following the formula:  Nmolecules =  
6 x10
23 




3.6 Antibodies used for Immunophenotyping 
the following monoclonal antibodies: mouse anti-human HLA class I (clone B9.12);  mouse 
anti-human HLA class II DR (clone D1.12); mouse anti-human CD19 (clone HIB19, BD 
Pharmingen); mouse anti-human CD16 (clone3G8, BD Pharmingen, Milan, Italy); the above 
antibodies were revealed by FITC-labelled rabbit anti-mouse IgG  F(ab’)2 antiserum (Sigma, 
Milan, Italy);  FITC mouse anti-human CD3 (clone (UCHT1 BD Pharmingen); FITC mouse 
anti-human CD4 (clone RPA-T4, BD Pharmingen);  phycoerythrin (PE) mouse anti-human 
CD25 (clone M-A251, BD Pharmingen), PE-Cy5 mouse anti-human CD8a (clone RPA-T8; 
eBioscience, Milan, Italy) and AlexaFluor® 647 mouse anti-human CD127 (clone HIL-7R-
M21, BD Pharmingen). Incubation and staining procedures were as previously described 
(Pellegrini FP et al., 2012). 
 
3.7 Confocal microscopy  
Appropriate number of cells were plated onto a sterilized cover slip (pre-coated with D-
polylysine 0.1ug/ml, Sigma) placed in a six-well plate. After 24h, transfection with plasmid                         
coding for myc-HBZ or GFP-HBZ or different HBZ mutants was performed overnight as 
desired. The cells were then washed with PBS 1X three times and fixed with methanol (-
20 C) for 4-6 minutes. Cells were then washed three times with PBS, and incubated with a 
solution of 0.5 % BSA in PBS for 1 h. The anti-HBZ was then added as primary antibody and 
incubated overnight at 4 C. Alexa fluor 546 IgG1 goat anti-mouse was used as secondary 
antibody for detecting the monoclonal antibody. After three washes with PBS, finally the 
cover slip was mounted onto a glass slide using a drop of mounting medium and sealed. The 
images were visualized by a Leica confocal microscope. A similar protocol was used for 
HTLV-1 infected cells C5MJ and ATL-2s. For the infected cells, PBS was replaced by a 
PHEM (60mM pipes, 25mM Hepes, 10mM EGTA, 2mM mgcl2; pH 7.0) buffer to improve 
the signal and the fixation was done by using absolute ethanol (-20 C) for 4-6 minutes. To 
assess co-localization of HBZ with host cellular factors C5MJ, ATL-2s and  PH961 cells 
were reacted in a pairwise combination with the 4D4-F3 anti HBZ mAb antibody, and  either  
polyclonal rabbit anti-CBP,  anti-JunD, anti-p300, anti-CREB2, or anti-nucleolin. Anti-HBZ 
mAb was revealed by Alexa fluor 546-labeled goat anti-mouse IgG (red), whereas the other 




Cell lysate of ATL-2s, C5MJ, PH961 cells as well as cell lysates of 293T cells transfected 
with a vector coding for HBZ.myc were prepared by using a non-denaturing lysis buffer (NP-
40 1%, Tris-base 10mM Ph 7.4, Nacl 150mM, EDTA 2mM). Protein A sepharose beads (GE) 
were washed with the same lysis buffer and used for pre-clearing the lysate for 20 minutes at 
4C. A volume of 100µ of anti-HBZ supernatant was then added to the precleared lysate and 
incubated for 1 h at 4C. Protein A sepharose beads were washed with lysis buffer and added 
to the above lysate; followed by overnight incubation at 4C. The beads were then washed 
six times with the same buffer (one time in between with lysis buffer containing high salt 
500mM NACL). Finally the beads were resuspended in 50µl of loading buffer 2X, boiled and 
run on SDS gel. The membranes were then incubated with appropriate primary and secondary 
antibodies, exposed and developed.  
 
3.9 Anti-HBZ ascites generation 
To obtain high concentration of  monoclonal antibody, 4D4-F3 hybridoma cells were injected 
intraperitoneally in Balb/c mice pre-injected 1 week before with 0,4 ml of pristane (Sigma) 
Ascitic fluid was collected after 2-3 weeks aseptically by using a syringe needle tip (22G). 
The resulting fluid was centrifuged to collect the supernatant. Aliquotes were made and 
freezed at -80 degree celcius until use.  
 
3.10 cDNA synthesis and QRT-PCR 
Total RNA was extracted from 5 million cells using Trizol (Invitrogen, Carlsbad, USA) and 
cDNA synthesized from total mRNA by using Iscript (Bio-Rad) according to the 
manufacturer’s protocol. PCR was performed by using 1ul of RT reaction, Sybrgreen master 
mix (Life Technologies) and 10 uM each forward and reverse primers. The following primers 
were used for amplifying HBZ and hRPS7 transcripts: 5’-seq-3’ 
(ATGGCGGCCTCAGGGCTGT), 5’-seq-3’ (TGGAGGGCCCCGTCGCAG) and 5’-seq-3’ 
(TGGAGATGAACTCGGACCTC), 5’-seq-3’ (CGACCACCACCAACTTCAA) 
respectively. Q-RT-PCR was performed in an ABI Prism 7000 sequence detection system 
(Applied Biosystems) according to the manufacturer’s instruction. The house-keeping human 
ribosomal protein S7 (hRPS7) was used as a reference control in the PCR reaction. The Ct 
value for each gene was obtained and was used to calculate the delta Ct value for each cell 
type, by the formula CT = CT of target gene – CT of reference gene. The CT value was 
then calculated for each cell type by the formula, CT = CT of cell type – CT of 
standard. For our experiments the CT value of C5MJ was kept as standard. Finally, the 
relative expression value was calculated by the formula 2^- CT for each cell type.  
4. RESULTS 
4.1 HBZ.GST: production, purification and quantification 
In order to generate monoclonal antibody against HBZ, GST-tagged HBZ fusion protein was 
used as an immunizing antigen. HBZ.GST protein was expressed in a bacterial source as 
explained in materials and methods. The bacterial cell lysate was subjected to a GST pull 
down assay in order to purify the expressed fusion protein (Fig. 8).  Elution 1 and elution 2 
lanes (Fig. 8, lane 6 and 7,) contained the eluted material coming from beads washed with 
reduced glutathione. The eluted material (HBZ.GST fusion protein) was by using a BCA 
protein assay kit  and constructing a standard curve with know concentration of bovine serum 
albumin (BSA) (Fig. 9 and Fig. 10). The equation corresponding to R value of standard curve 
was used to calculate the unknown protein concentration. Substituting an absorbance value of 
1.199 for HBZ.GST (elution 1) in the equation generated, a protein concentration value of 
54.55 ng per ul  was found (Fig. 10). 
 
4.2 Anti-HBZ monoclonal antibody generation, screening, cloning and iso-
typing 
Mice was immunized with 10 ug of HBZ.GST purified protein. The immunization protocol 
was as described in materials and methods. Spleen cells of immunized mice were fused with 
myeloma cells (P3U1) using PEG (polyethylene glycol). The resulting hybridomas were 
selected in a HAT+ medium and screened by western blot (Fig. 11). In order to screen the 
fused hybridoma supernatant, myc-tagged HBZ fusion protein was expressed and verified by 
western blot (Fig 12). Out of 96 hybridomas screened, one designated 4D4 showed strong 
positivity (Fig 13). The specificity for HBZ was demonstrated by the reactivity of the 
hybridoma with different tagged HBZ protein (HBZ.myc).   
                     The original 4D4 hybridoma cells were cloned by limiting dilution to isolate 
purified monoclonal populations of cells from the bulk hybridoma culture. Supernatants from 
single clones were screened by using ELISA as described in materials and methods. Two 
clones D1 and F3 showed high positivity for anti-HBZ reactivity and two other B10 and C10 
showed slight positivity (Fig 14). In an attempt to verify the ELISA results above, only D1 
and F3 monoclone reacted against HBZ when screened by western blot (Fig 15). Among the 
two monoclones, 4D4.F3 was selected to be used for all further experiments unless otherwise 
mentioned. The anti-HBZ clone 4D4-F3 was isotyped as IgG1 with kappa light chain by 
using an ELISA kit (Fig. 16).      
 
4.3 The 4D4-F3 mAb recognizes an epitope in the BR1 region of HBZ 
protein  
In order to delineate the HBZ epitope region recognized by 4D4-F3, an epitope mapping was 
carried out. For this purpose lysates of Cos cells transfected with either wild type GFP-HBZ 
or a series of GFP-HBZ constructs were analyzed by western blot. As shown in the Fig. 17, A 
left western blot, 4D4-F3 mAb recognized all fragments including the basic region 1 (BR1) 
of HBZ, and particularly the isolated diagnostic BR1 fragment but not the isolated DBD 
fragment. On the basis of the above results, the epitope was mapped to the region between 
amino acids 97 to 133 (Fig 17B) including the BR1 region. In order to confirm that the 
different HBZ mutant proteins were indeed present in the corresponding lysate, the anti-
serum from the mouse immunized with HBZ-GST and whose spleen was used for cell fusion, 
was checked for reactivity with the various HBZ protein fragments. Results presented in Fig. 
17A, right panel,  clearly show the reactivity of the antiserum with all fragments including 
the DBD fragment which is not recognized by the anti-HBZ F3 monoclonal antibody. Figure 
17B summarizes the results of epitope mapping, listing all the different HBZ constructs used  
and their size. 
 
4.4 Sub-cellular localization of HBZ and its constructs as assessed by the 
4D4-F3 monoclonal antibody   
4D4-F3 mAb was used to assess the localization and the distribution of HBZ in transfected 
cells. Previous studies using green fluorescence protein (GFP)-tagged HBZ or myc-tagged 
HBZ constructs transfected in Cos or 293T cells have documented a nuclear localization of 
HBZ in characteristic nuclear speckles (Gaudray. G et al., 2002). In our hands, GFP-HBZ 
transfected in 293T cells also showed a distinct nuclear speckled distribution (Fig 18) coming 
from GFP fluorescence. When the same cells were incubated with the 4D4-F3 mAb very 
intense stainig in the speckle-like nuclear structure was identified with a virtually complete 
overlap with the GFP-HBZ staining (Fig. 18, merge column). Interestingly, however, when 
GFP-HBZ deletion mutants were analyzed, a more refined and selective staining by the 4D4-
F3 antibody was observed (Fig. 19). For example nuclear GFP-∆ZIP  and GFP-∆AD  
fragments often displayed, beside spleckle-like distribution, strong green fluorescence 
staining in nuclear aggregates that were not detected by the 4D4-F3 which instead 
specifically evidentiated only the speckle-like structrures (see corresponding panels in Fig. 
19), strongly suggesting that those GFP-related aggregates are indeed an artifact due to the 
GFP and not a real signal due to ∆ZIP  and ∆AD localization. Virtual overlap in the staining 
between GFP and 4D4-F3 antibody was instead found for the mostly cytoplasmic BR1 and 
the mostly nuclear BR1-BR2-DBD HBZ fragments (see corresponding panels in Fig. 19), 
although, again, staining with 4D4-F3 was more refined and precise particularly for those few 
nuclear speckles observed with the BR1 fragment. Importantly, the DBD fragment was only 
evidentiated by the green fluorescence associated to the GFP-DBD construct and not by the  
4D4-F3 antibody, further confirming epitope mapping by western blot (Fig. 17). 
 
4.5 Untagged exogenous HBZ detected by 4D4-F3 
To assess whether the specificity of 4D4-F3 for HBZ was in any way affected by tagging the 
protein, an untagged HBZ contruct was synthesized and transfected in293T cells. Briefly, the 
vector backbone and HBZ insert for DNA ligation were restricted with XbaI and HIndIII 
(Fig. 20A). The ligation product upon restriction check by EcoR1 and BamH1 (Fig. 20B) was 
used for protein expression. The ability of 4D4.F3 anti-HBZ monoclonal antibody to detect 
untagged HBZ protein expressed by the newly generated DNA vector in transfected cells was 
confirmed by western blot and confocal microscopy (Fig. 21). Untagged HBZ protein 
migrates slightly above 25KDa (Fig. 21A) in contrast to myc-tagged HBZ protein which 
migrates at 36 KDa. Untagged HBZ conserved the characteristic speckle-like distribution in 
the nucleus observed also with the myc-tagged protein (Fig. 21B). These results confirm that 
the 4D4-F3 mAb can indeed recognize an epitope whose antigenicity is not affected by 
tagging the HBZ protein, and thus paved the way to use the mAb for detection analysis in 
endogenously synthesized HBZ in HTLV-1 naturally infected and in HTLV-1 dependent 
ATL tumor cells. 
 
 
4.6 Visualization of endogenous HBZ protein in HTLV-1 infected and in 
ATL tumor cells  by  4D4-F3 mAb  
Having demonstrated the specificity of the 4D4-F3 mAb both biochemically and 
phenotypically in HBZ transfected cell lines, it was then investigated the crucial aspect of 
detection and cellular distribution of endogenously made HBZ in HTLV-1 infected cells and 
cell lines. To this purpose three distinct cell lines were used: fresh peripheral blood 
mononuclear cells (PBMC) from a patient (PH961) suffering of ATL and two distinct cell 
lines, the HTLV-1 chronically infected C5MJ cell line (Sankichi H et al., 2006)  and the 
ATL-2s cell line (Maeda M et al., 1985) derived from a patient with Adult T cell 
leukemia/lymphoma. Preliminary analysis of the cell surface phenotype of C5MJ, ATL-2s 
and patient PH961 cells showed that C5MJ expresses CD4 and CD25 but not CD3, while 
ATL-2s did not express appreciable amounts of any of these matkers. On the other hand 
PBMC of the ATL patient  PH961 expressed CD3 and CD25 in 100% of the cells and CD4 in 
26% of the cells (Fig. 22). Results of confocal microscopy analysis are depicted in Figure 23. 
In all three HTLV-1 infected cells/ cell lines (C5MJ, ATL-2s and Ph961), HBZ was clearly 
detected by the 4D4-F3 mAb in the characteristic speckled-like structures in the nucleus. 
However, and importantly, both the intensity of fluorescence and the number of HBZ-
positive cells was substantially different from the ones detected in 293T cells transiently 
transfected with HBZ (compare boxed panels in Fig. 23). Low intensity of fluorescence in 
C5MJ, ATL-2s and PH961 was expected as these cells are endogenously producing HBZ as 
results of their HTLV-1 infection and HTLV-1-dependent oncogenic transformation. More 
interestingly however was the fact that the percentage of HBZ positive cells detected as 
positive by the 4D4-F3 mAb were different for each cell type. The average of HBZ positive 
cells was 75% for C5MJ, 100% for ATL-2s and 80% for PH961 cells, as assessed in at least 
three independent experiments (Fig. 23). This could be due to the detection threshold of our 
anti-HBZ antibody. Nevertheless these results clearly indicated that the expression of HBZ 
can substantially fluctuates even in HTLV-1 chronically infected or in ATLL patient-derived 
tumor cells.  
 
4.7 Quantification of endogenous HBZ protein in HTLV-1 infected and in 
ATL tumor cells  by the 4D4-F3 mAb.  
It was further investigated whether the 4D4-F3 antibody could be used to estimate the amount 
of HBZ protein present in HTLV-1 infected and in ATL tumor cell lines. To this purpose a 
careful quantification of purified GST-tagged HBZ protein by western blotting was 
performed to assess the detection limit of the 4D4-F3 antibody and to construct a 
corresponding curve. As little as 3.12ng of HBZ protein could be detected by this approach 
(Fig. 24A). Subsequently western blot analysis of distinct dilutions of cell lysates from a 
fixed number of myc-tagged HBZ-transfected 293T cells was performed  (Fig. 24B) and 
plotted the corresponding densitometry data on the curve constructed with the GST-tagged 
HBZ. This allowed us to define a provisional value of the amount of HBZ present in the 
transfected cells on a per cell basis by taking into account the percentage of HBZ transfected 
cells as shown in Figure 23. This value was 34,72x10
-3 
pg/cell, corresponding to 8x10
5 
molecules/cell (assuming a  molecular weight of 36 kDa for myc-HBZ). Similar experiments 
were performed with cell lysates from C5MJ, ATL-2s  and PH961 patient cells (Fig 24C). It 
must be stressed that in order to visualize by western blot specific HBZ bands in C5MJ, 




 cells as compared to 
3x10
6 
 HBZ-transfected 293T cells. Assuming a molecular weight of 26 kDa for endogenous 
HBZ, it was estimated that HBZ-positive C5MJ and ATL-2s cell lines contained an average 
of 1,04x10
-3
 pg/cell corresponding to 24.000 molecules/cell, and  1,56x10
-3 
pg/cell 
corresponding to 36.000  molecules/cell, respectively. In patient PH961 cells it was estimated 
an average of 0,78x10
-3
 pg/cell corresponding to 18.000 molecules/cell. Thus, with all the 
limitation of the analysis used, it was concluded that the amount of endogenously made HBZ 
molecules in freshly isolated ATL cells, in ATL cell line and in a chronically infected cell 
line was  comparatively much lower (22-44 fold) than the amount observed in transiently 
transfected 293T cells. 
 
4.8 Molecular interactions and cellular co-localizations between HBZ and 
cellular factors, in HBZ over-expressing 293T transfected cells and 
endogenously expressing HTLV-1 infected cells 
It has been reported that HBZ can interact in vivo with several transcription factors (Usui T et 
al., 2008; Basbous J et al., 2003; Zhao T et al., 2009) and it has been hypothesized that this 
interaction may have functional importance  for the pathological role played by HBZ in 
HTLV-1-infected patients (Barbeau B et al., 2013). However most of the experiments 
demonstrating HBZ-host factors interaction and co-localization have been carried out in cells 
over-expressing HBZ, mostly HBZ tagged with several easily identifiable markers against 
which antibodies are available. In addition, because of lack of appropriate higly purified and 
high affinity anti-HBZ antibody (most experiments in this line have been performed with an 
anti-HBZ rabbit antibody originally produced by Gaudray G et al., 2001), a careful analysis 
of the interaction-colocalization between HBZ and cellular factors was indeed prevented in 
endogenously HBZ  expressing cells such as HTLV-1 infected or ATL tumor cells.  The 
4D4-F3 anti-HBZ mAb was then used to assess the possible biochemical interactions and 
subcellular co-localizations of HBZ with cellular factors in ATL tumor cells and in C5MJ 
cells. We first checked the possible in vivo interaction between HBZ and two crucial nuclear 
factors such as JunD and CBP that are involved in several steps of both HTLV-1 replication 
and regulation of cellular gene expression. Cell extracts derived from C5MJ, ATL-2s and, 
from PBMC patient PH961 were first immunoprecipitated with the 4D4-F3 mAb and the 
resulting immunoprecipitate analyzed by SDS-PAGE and western blotting with specific 
antibodies for the presence of JunD and CBP. Results shown in Figure 25 indicate that 
endogenous HBZ interacts with both JunD and CBP (Fig. 25, lower panel), although to 
different extent depending on the cell analyzed and the amount of HBZ expressed. Indeed, 
both CBP and JunD interactions with HBZ were better detected in C5MJ and ATL-2s than in 
PH961 cells. This correlated with the higher amount of HBZ expressed in the first two cells 
compared to the patient ATL tumor cells. The overexpression of HBZ in 293T cells 
expressing endogenous CBP and JunD at levels comparable to HTLV-1 infected cells, 
resulted in a stronger interaction with both cellular factors, again suggesting that the limiting 
factor for the biological interactions was the concentration of HBZ present in the cell. 
          To further investigate the extent and the subcellular location of possible intracellular 
interaction between HBZ and cellular factors in HTLV-1 infected and ATL tumor cells, an 
extensive analysis by confocal microscopy was carried out. In this case the analysis included 
not only CBP and JunD but also other nuclear factors such as p300 and CREB-2, as well as 
nucleolin a marker of nucleoli. Figure 26  shows the results of such analysis in C5MJ, Figure 
27 in ATL-2s , and Figure 28 in patient PH961 cells. For all three figures, in the first series of 
vertical panels is depicted the distribution of HBZ protein (red fluorescence), in the second 
series of vertical panels the staining pattern of the various nuclear markers listed in each 
panel (green fluorescence) and in the third series of vertical panels the merged fluorescence. 
The fourth series  of vertical panels depicts the peak fluorescence distribution along a single 
line section (ROI) of the corresponding markers to better define specific co-localizations. The 
fifth series of vertical panels shows the phase contrast image of the cell(s) analyzed. A 
common feature, irrespective of the cell analyzed, was that only part of HBZ spots 
colocalized with those of either one of the various markers analyzed. A relatively higher 
colocalization was observed between HBZ and CREB-2 in C5MJ and ATL-2s cell lines, 
although this was not the case in patient PH961 ATL tumor cells.  
A second important feature was related to PH961 cells in which all markers showed a 
relatively lower expression compared to the two cell lines, probably reflecting the fact the 
immortalization and in vitro tumor growth induce a generalized overexpression of genes 
involved in the fine homeostasis of cell growth. Within the above mentioned limits, HBZ 
colocalized with CBP and p300 better in C5MJ than in ATL-2s. JunD was diffusely 
expressed in ATL-2s with respect to both C5MJ and patient PH961 cells, rendering difficult 
the appreciation of HBZ-JunD colocalization in ATL-2s cells. Instead a detectable 
colocalization between HBZ and JunD was observed in both C5MJ and patient PH961 cells. 
HBZ did not colocalize with nucleolin in any of the cells under study, indicating that the 




5. DISCUSSION   
HBZ is an important HTLV-1 viral oncogene that is strongly implicated in the neoplastic 
transformation leading to ATL (Matsuoka M et al., 2007). In contrast to Tax-1 oncogene, 
required to initiate neoplastic transformation, but not be to maintain the oncogenic process, 
HBZ is constantly found in ATL cells (Matsuoka M et al., 2013). For lack of suitable 
reagents, however, this expression has been assessed mostly at the level of HBZ mRNA, and 
mRNA may not be the best suitable marker for HBZ protein expression (Suemori K., 2009). 
In fact, previous reports have shown that HBZ in its protein form is scarcely produced in the 
infected cells and is not, or only marginally, discriminated from uninfected cells by HBZ 
specific CTLs (Suemori K., 2009) (Hilburn S., 2011). It is therefore extremely important to 
define its modality of expression, amount, localization and pattern of interaction with cellular 
factors during HTLV-1 infection and particularly in ATLL cells. The above parameters can 
be defined in vivo only by using tools that can evidence endogenous HBZ protein. Among 
these tools, specific monoclonal antibodies are certainly the most appropriate. Indeed, the use 
of the first described anti-HBZ mAb, 4D4-F3, specific  for an epitope within the 97-135 aa 
region,  has allowed us to characterize for the first time the expression and the localization of 
HBZ molecules in chronically infected HTLV-1 positive cells as well as in cells from an 
ATL patients, either as an established cell line (ATL-2s), or as fresh tumor cells from patient 
PMBC. Moreover, for the first time an estimation of the number of HBZ molecules expressed 
in HTLV-1 infected and ATL tumor cells could be obtained.  
Naturally expressed HBZ protein localized in the nucleus with a similar speckle-like 
distribution as the one observed in cells transfected with tagged HBZ protein. However 
several previously described aggregates of nuclear HBZ were shown to be artifacts of 
chimeric proteins, particularly in the case of studies conducted with GFP-HBZ constructs. 
These findings emphasize the usefulness of our anti-HBZ mAb to better define the 
intracellular pattern of expression of HBZ. Confocal microscopy analysis of C5MJ, ATL-2s 
and particularly PBMC of the PH961 ATL patient indicated that the vast majority of the cells 
expressed HBZ. The percentage of positive cells varied from  75% in C5MJ,  to  80% in 
PH961 ATL patient cells, and virtually 100% in ATL-2s cells. The results obtained in fresh 
PBMC of the PH961 ATL patient are of  interest since they indicate that not only the vast 
majority of the PBMC are ATL tumor cells but also that virtually all of them express HBZ 
protein. PH961 patient ATL cells displayed a cell surface phenotype with 100% of the cells  
coexpressing CD3 and CD25 molecules,  compatible with a T cell-activated phenotype, 
although these cells were only 26% positive for CD4 and negative for CD8 cell surface 
molecules. Thus most of the leukemic cells did not present the phenotypic characteristics of 
regulatory T cells (Tregs, CD4+/CD25+) or effector/memory T cells supposed to be the 
major targets of HTLV-1-mediated cellular  transformation (Karube K et al., 2004)( Satou Y 
et al., 2011) (Toulza F et al., 2008). More refined studies are presently underway to further 
clarify the phenotype and the possible functional correlates of CD3+/CD25+/CD4- and 
CD3+/CD25+/CD4+  cells in PH961 patient. It must be stressed, however, that also the cell 
surface phenotype of the ATL-2s cell line  was rather peculiar, as ATL-2s cells were negative 
for CD3 and CD4 and expressed only a very limited amount of CD25 molecules (Figure 22). 
The availability of 4D4-F3 mAb has allowed for the first time to estimate the number of HBZ 
molecules expressed on a per-cell basis in chronically infected C5MJ and in ATL tumor cells. 
In the three cells  this number was far less (22 to 44 fold less) than the one expressed in HBZ-
transfected cells such as 293T cells used by most investigators to characterize the pattern of 
expression, the co-localization and the possible interaction of HBZ with cellular factors. In 
absolute number C5MJ, ATL-2s and patient PH961 cells contained 24.000, 36.000 and 
18.000 molecules per cell, compared to an average o 800.000 molecules observed in HBZ-
transfected 293T cells. These results may help to better understand and evaluate the 
quantitative expression of HBZ during the various phases of HTLV-1 infection leading to 
chronic infection and eventually to neoplastic transformation. 
Many nuclear factors have been reported to interact  with HBZ. However most of these 
interactions were assessed in 293T or COS cells transfected with tagged HBZ, thus in HBZ 
overexpression conditions and in non physiological cellular models of HBZ expression. In 
this study we demonstrated  that endogenous HBZ expressed in chronically infected and in 
ATL tumor cells interact in vivo with cellular transcription factors that are involved both in 
the control of HTLV-1 replication and in the host cell homeostasis. We could show that 
native HBZ can interact with CBP and JunD both in C5MJ and in the ATL tumor cells, 
although to different extent. In the two cell lines C5MJ and ATL-2s the interaction was 
consistently higher than the one observed in fresh ATL patient PH961 cells and partially 
correlated to the higher expression of HBZ protein in the former cell lines compared to the 
latter fresh tumor cells. These results definitively demonstrate that native HBZ can indeed 
interact in vivo with CBP and JunD in situations of “physiological” expression of the viral 
protein. Whether these interactions, as well as other described interactions such as the HBZ-
CREB-2 and HBZ-p300, have a crucial functional role on the homeostasis of HTLV-1-
infected cells and a causative implication in the cellular transformation leading to the ATL 
phenotype, it was not addressed in this study. Nevertheless, in C5MJ, ATL-2s and patient 
PH961 cells careful confocal microscopy analysis of  co-localization of HBZ with either 
CBP, JunD, p300 or CREB-2 demonstrated a partial, often only a minor, colocalization 
between the viral protein and the cellular nuclear factors. Thus, possible functional correlates 
of each single interaction of HBZ with the above nuclear factors in HTLV-1 infected and 
ATL cells should be framed within these findings.  
In conclusion, the availability of the 4D4-F3 anti-HBZ mAb may significantly contribute to a 
better delineation of the role and presence of HBZ during HTLV-1 infection and cellular 
transformation.  
6. FUTURE PERSPECTIVES 
The severity of HTLV-1 infection is merely dictated by the underlying complex mechanism 
of infection involved. Although it is theorized that a cell to cell contact may be responsible 
for the spread of this infection, steps involved in HTLV-1 oncogenesis are yet to be fully 
understood. Understanding differential viral protein expression and their interaction/ 
localization with host factors in the infected cells would undoubtedly help in understanding 
different viral strategies to overcome immune response. Thus it becomes crucially important 
to study one of the key protein candidate involved in HTLV-1 infection, the HTLV-1 bZIP 
factor protein (HBZ). By generating the firstly reported anti-HBZ monoclonal antibody it will 
be feasible to detect and study HBZ protein in a detailed manner. Experiments done as a part 
of this PhD thesis project surely confirms the previously debated view of whether HBZ at 
protein level is expressed in the HTLV-1 infected cells or not. Further studies would focus on 
the interaction of HBZ protein with cellular factors in HTLV-1 infected cells. These 
experiments will show if the previously reported interaction of over-expressed HBZ (in 
transfected cells) with cellular factors are indeed of physiological relevance or not. Moreover, 
screening the leukemic cells from different patients, would show how many and which cell 
types are expressing HBZ protein. These studies can also be extended to cells from patients 
with HAM/ TSP or even asymptomatic carriers of HTLV-1 infection. All of the studies 
mentioned above along with certain protein kinetics assay would throw light on the 
importance of HBZ in cellular transformation and maintenance of infectivity. 
 








Figure 17: Epitope assignment of 4D4-F3 anti-HBZ mAb 
A) Western blot analysis of full length GFP-tagged HBZ (HBZ) and a series of GFP-tagged 
HBZ fragments listed in the top of the left and right panels. Briefly, 293T cells were 
transfected with the various encoding GFP-HBZ cDNAs, with empty plasmid (mock) or with 
GFP cDNA (GFP). Twenty four hours after transfection cell lysates were prepared and 
analyzed by western blotting using the 4D4-F3 anti HBZ mAb (left panel) or the anti-HBZ 
antiserum prepared from the same animal used for somatic cell fusion (right panel). B)- 
Schematic representation of the same results depicted in A. The various HBZ constructs are 
listed on the left side followed by bars representing size and regions of  the specific fragment 
analyzed. Numbers indicate the specific aminoacid position in the various fragments. Plus (+) 
and minus (-) symbols indicate positive or negative reactivity, respectively, of the 4D4-F3 
mAb. Abbreviations: AD, activation domain; BR1, basic region 1; BR2, basic region 2; 






Figure 22: Cell surface phenotype of C5MJ, ATL-2s and patient PH961 cells 
Cell surface phenotype of C5MJ, ATL-2s  cell lines and of peripheral blood mononuclear 
cells from ATL patient PH961 was assessed by immunofluorescence and flow cytometry. 
The various cell surface markers listed in the top right of each histogram were assessed by 
specific monoclonal antibodies either directly labeled with fluorochromes (CD3, CD4, CD8, 
CD25, CD19, and CD16), or unlabeled (HLA class I and HLA class II DR) followed by 
FITC-labeled rabbit anti-mouse IgG. Specific fluorescence is represented by the bold 
histogram; negative isotype control is represented by the thin histogram. Values are 
expressed in the abscissa as mean fluorescence in arbitrary units (a.u.). 
Figure 23: Expression and localization of endogenous HBZ in HTLV-1 chronically 
infected and in ATL tumor cells 
C5MJ (HTLV-1  chronically infected),  ATL-2s (ATL tumor cell line) and PH961 (PMBC of 
an ATL patient) were stained with the 4D4-F3 antibody, followed by Alexa fluor 546-labeled 
goat anti-mouse antibody and analyzed by confocal microscopy. 293T cells  transiently 
transfected with myc-HBZ cDNA plasmid were used as comparison. Differential interference 
contrast image of each cell field analyzed  is shown in the left side of each confocal picture. 
The small round yellow shade points to a HBZ positive cell shown enlarged in the yellow 
square insert. In parenthesis the percentage of HBZ-positive cells calculated by counting at 
least 200 cells. 
 
Figure 24: Quantification of endogenous HBZ expression in HTLV-1 chronically 
infected and in ATL tumor cells 
In all panels, HBZ protein was migrated in SDS-PAGE gels. After blotting onto 
nitrocellulose membranes, HBZ protein was detected by 4D4-F3 mAb followed by HRP 
conjugated anti-mouse antbody A)- Purified GST-tagged HBZ protein at different nanogram 
(ng) concentration was used to construct a detection curve .  B)- Western blots of serial 
dilutions of cell lysate from 293T cells transfected with myc-tagged (HBZ.myc). In this 
experiment 3µg of HBZ.myc were transfected in 5 million cells. After transfection, cells were 
lysed in 1ml of lysis buffer and 40 µl of cell lysate, either undiluted or diluted as listed, used 
for western blotting. C)- Western blots of cell lysate from C5MJ, ATL-2s, and PH961 patient 
ATL tumor cells. In this experiment 50 million cells were lysed in 2ml of lysis buffer and 40 
µl of undiluted cell lysate used for western blotting. 
In the right side insert of  the Figure are listed the calculated values of HBZ picograms (pg) 
per cell and the deduced number of HBZ molecules per cells. For further details see the text. 
 
Figure 25: in vivo interaction of endogenous HBZ with intracellular molecules. 
The possible in vivo interaction between endogenous HBZ and CBP or JunD was assessed by 
co-immunoprecipitation assay. Lower panel: cell lysates from 50 million cells of C5MJ, 
ATL-2s or PH961 ATL patient, prepared as described in the legend to Figure 4, were 
immunoprecipitated by using HBZ covalently linked to CNBr-activated Sepharose 4B beads 
(IP anti-HBZ). After elution from HBZ-Sepharose 4B beads, the eluted material was 
migrated on SDS-PAGE gels, blotted on nitrocellulose membranes and probed with 
antibodies specific for either anti-CBP, anti-JunD or with the 4D4-F3 mAb (anti-HBZ). 
Upper panel: prior immunoprecipitation 40 µl of cell lysate were used to assess the presence 
of the specific protein by western blot (input).
 
Figure 26: Co-localization of endogenous HBZ with intracellular factors in C5MJ cells 
C5MJ cells were reacted in a pairwise combination with the  4D4-F3 anti HBZ mAb 
antibody, and  either  polyclonal rabbit anti-CBP,  anti-JunD, anti p300, anti CREB2, or anti 
nucleolin antisera. Anti-HBZ mAb was revealed by Alexa fluor 546-labeled goat anti-mouse 
IgG (red), whereas the other rabbit antisera were revealed by  Alexa fluor 488-labeled  goat 
anti-rabbit antibodies (green). The MERGE column panels represent the merge between the 
Alexa fluor 546  and the Alexa fluor 488 signals. A colocalization of HBZ with either one of 
the intracellular factors results in a yellow colour. The reference of intensity (ROI) drawn 
along mid-nucleus level of the merge image (insert) is represented by red and green peaks in 
the histogram (red for HBZ and green for  the intracellular factor).  Differential interference 
contrast (DIC) image of each cell field analyzed  is shown in the last vertical series of panels. 
Figure 27: Co-localization of endogenous HBZ with intracellular factors in ATL-2s 
cells 
ATL-2s cells were reacted in a pairwise combination with the  4D4-F3 anti HBZ mAb 
antibody, and  either  polyclonal rabbit anti-CBP,  anti-JunD, anti p300, anti CREB2, or anti 
nucleolin. For detection and other relevant informations see the legend to Figure 26.
Figure 28: Co-localization of endogenous HBZ with intracellular factors in PH961 
cells 
PH961 patient cells were reacted in a pairwise combination with the  4D4-F3 anti HBZ mAb 
antibody, and  either  polyclonal rabbit anti-CBP,  anti-JunD, anti p300, anti CREB2, or anti 
nucleolin. For detection and other relevant informations see the legend to Figure 26. 
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